Enhanced Thiosuccinyl-Crosslinked Hemoglobin Conjugates for Improved Stability and Efficiency

This inventive concept presents a series of direct improvements and enhancements to the original thiosuccinyl-crosslinked hemoglobin conjugates, addressing limitations in stability, efficiency, and scalability. The new claims introduce innovative solutions for conjugate preparation, storage, and formulation, leading to enhanced shelf-life, reduced immunogenicity, and improved solubility.

The original patent disclosed thiosuccinyl-crosslinked hemoglobin conjugates with polyethylene glycol (PEG) modifications. However, these conjugates faced limitations in terms of stability, efficiency, and scalability. The new inventive concept addresses these limitations by introducing novel systems, methods, and compositions that enhance the conjugates' performance and usability.

The new claims comprise a system for preparing thiosuccinyl-crosslinked hemoglobin conjugates using a microfluidic reactor, which enables controlled mixing of reactants and efficient separation of conjugates from unreacted species. Additionally, a method for enhancing the shelf-life of these conjugates involves storing them in a lyophilized state at controlled temperature and humidity. A pharmaceutical composition featuring a stabilizing agent is also disclosed, which enhances the conjugates' resistance to oxidation and thermal degradation. Furthermore, a process for large-scale production of thiosuccinyl-crosslinked hemoglobin conjugates using a continuous flow reactor and downstream centrifugation module is presented. Finally, a new thiosuccinyl-crosslinked hemoglobin conjugate with improved solubility and reduced immunogenicity is disclosed, comprising a tetrameric hemoglobin modified with a hydrophilic polymer and a thiosuccinyl crosslinking moiety.

The new claims introduce novel solutions that are not obvious from the original patent. The use of microfluidic reactors, lyophilization, and stabilizing agents represents a significant departure from the prior art, providing unexpected improvements in stability, efficiency, and scalability. The new conjugate composition with improved solubility and reduced immunogenicity also constitutes a non-obvious advancement.

Alternative embodiments of the inventive concept could include the use of different microfluidic reactor designs, various stabilizing agents, or alternative polymer modifications. Additionally, the conjugates could be formulated with different excipients or administered through various routes to achieve specific therapeutic effects.

The enhanced thiosuccinyl-crosslinked hemoglobin conjugates have significant commercial potential in the pharmaceutical industry, particularly in the development of oxygen therapeutics and blood substitutes. The improved stability, efficiency, and scalability of the conjugates could lead to increased adoption and reduced costs, making them more competitive in the market.